Moore M R, Conover J L, Franks K M
Department of Biochemistry and Molecular Biology, Marshall University School of Medicine, Huntington, West Virginia, 25704, USA.
Biochem Biophys Res Commun. 2000 Nov 2;277(3):650-4. doi: 10.1006/bbrc.2000.3728.
The effect of progestins on proliferation of breast cancer has been a controversial area. We have consistently reported progestin stimulation of proliferation in the progesterone receptor-rich human breast cancer cell line T47D. Other authors, under other conditions, have agreed that progestins stimulate, but for just one turn of the cell cycle. To our knowledge, this is the first in vitro report to show progestin stimulation of human breast cancer cell growth for multiple, probably unlimited, cell cycles, while control cells are dying. This is accompanied by progestin up-regulation of the antiapoptotic protein bcl-xL, no effect on the proapoptotic protein bax, and, surprisingly, diminution of the antiapoptotic protein bcl-2. Thus, progestins both serve as survival factors and stimulate proliferation, implying a possible similar role in breast cancer patients. The data support the notion that many patients may benefit more from combined antiprogestin-antiestrogen therapy than from antiestrogen alone, and suggest bcl-x(L) as a possible target for breast cancer therapy.
孕激素对乳腺癌增殖的影响一直是一个有争议的领域。我们一直报道孕激素能刺激富含孕激素受体的人乳腺癌细胞系T47D的增殖。其他作者在其他条件下也认同孕激素能刺激细胞增殖,但仅作用于一个细胞周期。据我们所知,这是第一份体外研究报告,表明孕激素能刺激人乳腺癌细胞在多个(可能是无限的)细胞周期中生长,而对照细胞正在死亡。这伴随着孕激素上调抗凋亡蛋白bcl-xL,对促凋亡蛋白bax没有影响,且令人惊讶的是,抗凋亡蛋白bcl-2减少。因此,孕激素既能作为生存因子又能刺激增殖,这意味着在乳腺癌患者中可能有类似作用。这些数据支持这样一种观点,即许多患者联合使用抗孕激素-抗雌激素疗法可能比单独使用抗雌激素疗法获益更多,并提示bcl-x(L)可能是乳腺癌治疗的一个靶点。